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Abstract
A Korean nationwide surveillance on circulating rotavirus strains
was conducted from September 2000 to August 2007 aiming to
obtain prevaccine data for predicting vaccine effectiveness. The
predominant strains among the 2779 strains analyzed varied
annually and only approximately 50% had either a G or a P anti-
gen present in both RotaTeq (Merck & Co. Inc., Whitehouse
Station, NJ, USA) and Rotarix (GlaxoSmithKline, Brentford, UK).
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Group A rotaviruses (RV-A) are the leading cause of severe
acute gastroenteritis among infants and young children.
In developing countries, severe diarrhoea caused by human
RV-A results in an estimated 600 000 childhood deaths
annually; worldwide, this disease results in 2 million hospitaliza-
tions [1–3]. Although the RV-A infection-associated mortality
is relatively low in industrialized countries, RV-A diarrhoea
remains a major reason for visits to paediatric clinics and emer-
gency departments, as well as inpatient hospitalizations.
Two new RV-A vaccines, Rotarix (GlaxoSmithKline,
Brentford, UK) and RotaTeq (Merck & Co. Inc., Whitehouse
Station, NJ, USA), have been licensed in approximately 100
countries worldwide and are already part of the national
vaccination schedules of several countries [4,5]. RotaTeq,
introduced in South Korea (hereafter referred to as Korea)
in September 2007, is a pentavalent vaccine constructed by
introducing common human RV-A serotype antigen genes
(G1–G4, P[8]) into a bovine RV-A parent strain to create
ﬁve different reassortant strains [4]. Rotarix is a monovalent
vaccine based on an attenuated genotype G1P[8] strain that
is designed to provide serotype-speciﬁc and heterotypic
protection against common RV-A serotypes; it was launched
in July 2008 in Korea.
RV-A belong to the family Reoviridae. Viral particles are
nonenveloped, and triple-layered protein capsids enclose the
genome of 11 dsRNA segments. The outer layer of the viral
capsid is composed of two structural proteins: VP4, a prote-
ase-cleaved or P protein, and VP7, a glycoprotein or G
protein [1]. These proteins carry the major antigenic deter-
minants, which elicit neutralization antibodies, form the basis
for the dual molecular classiﬁcation scheme that indicates
the viral G and P serotypes, and play key roles in the devel-
opment of protective immunity [1]. Because VP4 and VP7
genes reassort independently from one another during mixed
infection, the G and P genotypes are monitored during sur-
veillance studies. Such surveillance studies help to identify
the most important strains in circulation before the intro-
duction of RV-A vaccines and to evaluate the effectiveness of
the vaccines against the common genotypes.
The Korea Centers for Disease Control and Prevention, in
collaboration with 16 laboratories of local public health
institutes and participants (n > 100) in a sentinel hospital,
initiated an agent surveillance system for acute gastroenteritis
in 1999.
Faecal samples testing positive for the group A RV-A anti-
gen by antigen-capturing ELISA (IDEIA Rotavirus; Dako Diag-
nostics, Ely, UK) were collected for genotyping using reverse
transcription-PCR, as described previously [6]. From Septem-
ber 2000 until August 2007, faecal samples from 164 081
patients with acute gastroenteritis were analyzed. Of these
samples, 19 845 (12%, range 9.1%–15%; 2000–2001 to 2006–
2007) were positive for RV-A by ELISA. The peak seasons of
RV-A infection were winter and spring, from December to
May (Fig. 1). During the ﬁrst two seasons, the highest num-
ber of RV-A infections was detected in April, whereas the
peak was in February, and a marked number of infections
was detected in May, from the 2002–2003 season onward.
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Using RT-PCR, we determined the G and P genotypes of
2779 RV-A strains received from around the country. Over-
all, 23.0% of the strains from the period 2000–2007 were
G1P[8], 18.8% were G3P[8], 18.3% were G2P[4] and 15.9%
were G4P[6] as the neonatal strain (Table 1); these four
strains represented 80.1% of all the strains analyzed. There
was considerable genotype diversity among strains, and the
incidence of predominant strains ﬂuctuated annually.
In brief, the most common strains were G2P[4] during
the ﬁrst two seasons, G3P[8] from 2002–2003 until
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FIG. 1. Temporal distribution of rotavirus infections from September 2000 to August 2007 in South Korea.
TABLE 1. Distribution of rotavirus genotypes in seven consecutive seasons of rotavirus infection from 2000 to 2007 in South
Korea
Strain group,
genotype
Number (%) of strains by season of rotavirus infection
2000–01
(n = 318)
2001–02
(n = 463)
2002–03
(n = 433)
2003–04
(n = 332)
2004–05
(n = 399)
2005–06
(n = 280)
2006–07
(n = 554)
Total
(n = 2779)
Common human strains 222 (69.81) 316 (68.25) 309 (71.36) 262 (78.92) 274 (68.67) 188 (67.14) 359 (64.80) 1,930 (69.45)
G1P[8] 104 (32.70) 143 (30.89) 79 (18.24) 39 (11.75) 52 (13.03) 72 (25.71) 289 (52.17) 778 (28.00)
G2P[4] 110 (34.59) 145 (31.32) 54 (12.47) 62 (18.67) 90 (22.56) 37 (13.21) 11 (1.99) 509 (18.32)
G3P[8] 6 (1.89) 13 (2.81) 124 (28.64) 155 (46.69) 108 (27.07) 71 (25.36) 45 (8.12) 522 (18.78)
G4P[8] 2 (0.63) 11 (2.37) 10 (2.31) 0 (0) 6 (1.50) 1 (0.36) 5 (0.90) 35 (1.26)
G9P[8] 0 (0) 4 (0.86) 42 (9.70) 6 (1.81) 18 (4.51) 7 (2.50) 9 (1.62) 86 (3.09)
Reassortants common
human strains
14 (4.40) 4 (0.86) 1 (0.23) 6 (1.81) 28 (7.02) 9 (3.21) 22 (3.97) 84 (3.02)
G1P[4] 7 (2.20) 2 (0.43) 1 (0.23) 0 (0) 3 (0.75) 3 (1.07) 8 (1.44) 24 (0.86)
G2P[8] 6 (1.89) 1 (0.22) 0 (0) 1 (0.30) 5 (1.25) 1 (0.36) 12 (2.17) 26 (0.94)
G3P[4] 0 (0) 0 (0) 0 (0) 2 (0.60) 10 (2.51) 2 (0.71) 0 (0) 14 (0.50)
G4P[4] 1 (0.31) 1 (0.22) 0 (0) 3 (0.90) 10 (2.51) 3 (1.07) 1 (0.18) 19 (0.68)
G9P[4] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.18) 1 (0.04)
Zoonotic 53 (16.67) 109 (23.54) 108 (24.94) 55 (16.57) 71 (17.79) 55 (19.64) 69 (12.45) 520 (18.71)
G1P[6] 21 (6.60) 6 (1.30) 3 (0.69) 5 (1.51) 0 (0) 3 (1.07) 1 (0.18) 39 (1.40)
G2P[6] 2 (0.63) 3 (0.65) 2 (0.46) 0 (0) 8 (2.01) 1 (0.36) 0 (0) 16 (0.58)
G2P[9] 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.18) 1 (0.04)
G3P[6] 1 (0.31) 4 (0.86) 2 (0.46) 0 (0) 0 (0) 1 (0.36) 0 (0) 8 (0.29)
G3P[10] 0 (0) 1 (0.22) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.04)
G4P[6] 29 (9.12) 86 (18.57) 98 (22.63) 50 (15.06) 62 (15.54) 49 (17.50) 67 (12.09) 441 (15.87)
G9P[6] 0 (0) 9 (1.94) 3 (0.69) 0 (0) 0 (0) 1 (0.36) 0 (0) 13 (0.47)
G10P[6] 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.25) 0 (0) 0 (0) 1 (0.04)
Partially typed strains 8 (2.52) 13 (2.80) 2 (0.46) 0 (0) 0 (0) 7 (2.50) 49 (8.84) 79 (2.84)
Mixed types 21 (6.60) 21 (4.54) 13 (3.00) 9 (2.71) 26 (6.52) 21 (7.50) 55 (9.93) 166 (5.97)
Bold indicates a signiﬁcant (p <0.001) change in the genotype distribution from one year to the next.
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2004–2005, and G1P[8] from the 2005–2006 season onward.
In the 2000–2001 season, 34.59% of the strains had genotype
G2P[4], although this percentage decreased from the 2001–
02 season. The number of cases with G3P[8] increased
(from 1.89% to 46.69%) during the ﬁrst four seasons and
decreased during the last three seasons (from 27.07% to
8.12%). G1P[8] had lower detection rates from 2003 to
2005 (<20%) than those reported in many countries [7];
however, the detection rates sharply increased in the 2006–
2007 season (52.17%). G9P[8] exhibited a peak prevalence of
9.7% in 2002–2003 but had much lower detection rates
except in 2003.
In the present study, the prevalence and distribution of
RV-A genotypes among cases of acute gastroenteritis in
Korea were investigated to predict whether the recently
introduced RV-A vaccines, Rotarix and RotaTeq, are sufﬁ-
cient for preventing RV-A infection. By nationwide surveil-
lance, we found that only approximately 50% of the strains
during the surveillance period had either a G or a P antigen
present in both the vaccines; the distribution of the circulat-
ing RV-A genotypes and the predominant strains varied from
year to year.
One of the hallmarks of such surveillance in the past dec-
ade as part of vaccine development programmes is the char-
acterization of a large diversity of serotypes among human
RV-A, with 110 P and G serotypes each and 140 P–G anti-
gen combinations being reported [5,7]. Such reports highlight
the ﬁndings on emerging serotypes (e.g. G9) that have
become globally common during recent years, other poten-
tially emerging serotypes (e.g. G12), as well as regionally
common serotypes (e.g. G5 and G8) [5,7–9]. The tracking of
these strains is a key component of surveillance studies (as
immunization programmes are introduced in individual coun-
tries) aiming to determine whether any of the strains can
evade the protective immunity provided by the vaccines.
Previous studies of the RV-A strains circulating in Korea
have shown that G1P[8] (36%) was the most prevalent
strain, followed by G3P[8] (16%), G4P[6] (8.9%) and G1P[6]
(8.2%), in the period from 2005 until 2007 [10], whereas the
reports spanning 2002–2004 indicate that 39% of the strains
were G9P[8], 24% were G1P[8], 17% were G3P[8] and 13%
were G2P[4] [11]. However, the previous data were rela-
tively limited in size as well as by the number of sites cov-
ered, and may not be representative of the whole country
(i.e. Korea). The present study is the ﬁrst extensive nation-
wide surveillance for circulating RV-A strains in Korea.
In the 2000–2001 season, the prevalence of G2P[4] was
as high as 34.6%. Recently, an increase in the incidence of
infection with the G2P[4] strain has been reported in Brazil,
where the monovalent G1P[8] RV-A vaccine is currently in
use [12–15]. This ﬁnding raises questions about the ability of
this vaccine to confer cross-protection against G2P[4] RV-A
-associated disease, although more evidence is required
before ﬁrm conclusions can be made [13]. Assessment of
the effectiveness of a vaccine against disease caused by spe-
ciﬁc strains after the introduction of the vaccine is impor-
tant, particularly against disease caused by serotypically
unique strains.
Fifteen out of 2779 strains identiﬁed during the present
study have both serotype antigens (e.g. G9P[4], G9P[6] and
G10P[6]), which are different from the serotype antigens of
the strains in either vaccine; in addition, they belong to a
genogroup that is different from those of the vaccine strains
(Table 1). The prevalence of G9P[6] strains is only 0.47%,
with a maximum of 1.94%, and single isolates of G9P[4] and
G10P[6] were also identiﬁed.
Further studies on vaccine effectiveness are needed to
determine whether such strains are more likely to evade
immunity provided by the new vaccines. As shown in
Table 1, several strains detected at very high frequencies
(12.5%–24.9%) had common G antigens (G1, G2, G3 or G4)
with uncommon P antigens [6] or [9]; G4P[6] was the major
strain among these strains. Therefore, unusual reassortants
of the common serotypes, such as G1P[4], possibly express
epitopes different from those of the parental P–G combina-
tions. Finally, some neutralization epitopes on the P serotype
antigen may be masked depending on the composition of the
other ten genes [16]. The proportion of reassortants of the
common human strains in the present study was approxi-
mately 3% (Table 1). It is difﬁcult to predict how vaccine
introduction will affect the diversity of the RV-A strains in
Korea. Therefore, it is important to monitor the impact of
vaccines on the prevalence of such unusual reassortants.
In summary, surveillance conducted over seven consecu-
tive RV-A seasons from 2000 until 2007 showed that only
approximately 50% of the strains had either a G or a P anti-
gen present in both RotaTeq and Rotarix. Strains with an
uncommon antigenic makeup circulated in all the seasons
during which larger numbers of strains were genotyped, indi-
cating that these strains may be endemic to Korea. The
maintenance of nationwide surveillance is essential for under-
standing the impact of new vaccines on the circulating RV-A
strains as well as the overall reduction in the prevalence of
RV-A diarrhea in Korea.
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Accuracy of bedside antigen tests in the
diagnosis of new inﬂuenza A/H1N1v
infection
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Abstract
To evaluate the clinical reliability of two rapid inﬂuenza detec-
tion tests (RIDTs), we analyzed 107 specimens from patients
with clinically suspected pandemic inﬂuenza A/H1N1v by these
tests as well as by real-time PCR as a standard. Both RIDTs had
a moderate sensitivity (28–32%), a high speciﬁcity (93–99%) and
a negative predictive value of 80%. These results will impact on
the clinical management and isolation precautions in patients
with suspected infection. Although a positive RITD is mostly
conﬁrmatory, a negative result in the presence of high clinical
likelihood of infection should be interpreted with caution and be
re-evaluated by PCR.
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During the outbreak of the pandemic inﬂuenza A (H1N1v) in
2009, tests for rapid detection of inﬂuenza antigens (RIDT)
were widely recommended and widely used as bedside
screening for inﬂuenza in suspected patients. These tests had
a high predicted sensitivity, which made them attractive as a
clinical screening test [1,2]. However, the parallel testing of
such patients by means of real-time PCR from the same
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